Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.

Chang, Anne Lynn S; Zaba, Lisa; Kwong, Bernice Y

Chang, Anne Lynn S; Zaba, Lisa; Kwong, Bernice Y.

Afiliación

Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address: alschang@stanford.edu.
Zaba L; Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
Kwong BY; Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

J Am Acad Dermatol ; 88(6): 1243-1255, 2023 06.

Article en En | MEDLINE | ID: mdl-37268391

Asunto(s)

Melanoma; Neoplasias Cutáneas; Humanos; Melanoma/patología; Neoplasias Cutáneas/tratamiento farmacológico; Neoplasias Cutáneas/patología; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Estudios Prospectivos; Inmunoterapia/efectos adversos; Queratinocitos/patología

Palabras clave

T-VEC; basal cell carcinoma; biologic; cemiplimab; cutaneous toxicity; imiquimod; immune-related adverse events; immunotherapy; keratinocyte carcinoma; oncologic outcomes; pembrolizumab; programmed cell death 1; programmed death; rechallenge; squamous cell carcinoma; steroid-sparing; talimogene laherparepvec; toll-like receptor 7

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Am Acad Dermatol Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google